Best-Value Medicine: Teriparatide 

The HSE-Medicines Management Programme (MMP) is undertaking a formal consultation phase as part of the process for the identification of a best-value medicine (BVM) for teriparatide.

The MMP roadmap for the prescribing of best-value biological (BVB) medicines in the Irish healthcare setting outlines the criteria that may be considered by the MMP in identifying the BVM for teriparatide.

Submissions are invited from all relevant stakeholders, and should be emailed to by 5pm on Wednesday 4th May 2022.